Alopecia areata investigational assessment guidelines - Part II

被引:489
作者
Olsen, EA
Hordinsky, MK
Price, VH
Roberts, JL
Shapiro, J
Canfield, D
Duvic, M
King, LE
McMichael, AJ
Randall, VA
Turner, ML
Sperling, L
Whiting, DA
Norris, D
机构
[1] Duke Univ, Med Ctr, Durham, NC 27710 USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Skin Care Ctr, Vancouver, BC, Canada
[6] Canfield Sci, Fairfield, NJ USA
[7] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Vanderbilt Univ, Nashville, TN USA
[9] Wake Forest Univ, Med Ctr, Winston Salem, NC 27109 USA
[10] Univ Bradford, Bradford BD7 1DP, W Yorkshire, England
[11] NIH, Bethesda, MD 20892 USA
[12] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[13] Baylor Hair Res & Treatment Ctr, Dallas, TX USA
[14] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA
关键词
D O I
10.1016/j.jaad.2003.09.032
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Alopecia areata is an immunologically mediated disease characterized by extreme variability not only in the time of initial onset of hair loss but in the duration, extent and pattern of hair loss during any given episode of active loss. These variables, as well as the unpredictable nature of spontaneous regrowth and lack of a uniform response to various therapies, has made clinical trials in alopecia areata difficult to plan and implement. In fact, there are currently no drugs FDA-approved specifically for the indication of alopecia areata. To help facilitate well-controlled clinical trials for alopecia areata, this National Alopecia Areata Foundation (NAAF) sponsored subgroup of investigators/clinicians experienced in clinical trials and/or in the clinical care of patients with alopecia areata has outlined some general principles and potential endpoints for clinical studies in alopecia areata. These guidelines build on the Alopecia Areata Investigational Assessment Guidelines published in 1999(1) which established baseline clinical staging and background information important to gather on any alopecia areata patient involved in clinical research.
引用
收藏
页码:440 / 447
页数:8
相关论文
共 14 条
[1]   THERAPEUTIC EXPERIMENTS IN ALOPECIA AREATA WITH ORALLY ADMINISTERED CORTISONE [J].
DILLAHA, CJ ;
ROTHMAN, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1952, 150 (06) :546-550
[2]   EVALUATION OF ANTHRALIN IN THE TREATMENT OF ALOPECIA-AREATA [J].
FIEDLERWEISS, VC ;
BUYS, CM .
ARCHIVES OF DERMATOLOGY, 1987, 123 (11) :1491-1493
[3]   TOPICAL MINOXIDIL DOSE-RESPONSE EFFECT IN ALOPECIA-AREATA [J].
FIEDLERWEISS, VC ;
WEST, DP ;
BUYS, CM ;
RUMSFIELD, JA .
ARCHIVES OF DERMATOLOGY, 1986, 122 (02) :180-182
[5]   A RANDOMIZED DOUBLE-BLIND-STUDY OF INOSIPLEX (ISOPRINOSINE) THERAPY IN PATIENTS WITH ALOPECIA TOTALIS [J].
GALBRAITH, GMP ;
THIERS, BH ;
JENSEN, J ;
HOEHLER, F .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1987, 16 (05) :977-983
[6]   ORAL CYCLOSPORINE FOR THE TREATMENT OF ALOPECIA-AREATA - A CLINICAL AND IMMUNOHISTOCHEMICAL ANALYSIS [J].
GUPTA, AK ;
ELLIS, CN ;
COOPER, KD ;
NICKOLOFF, BJ ;
HO, VC ;
CHAN, LS ;
HAMILTON, TA ;
TELLNER, DC ;
GRIFFITHS, CEM ;
VOORHEES, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 22 (02) :242-250
[7]   ALOPECIA AREATA - IMMUNOLOGICAL STUDIES AND TREATMENT WITH PREDNISONE [J].
KERN, F ;
HOFFMAN, WH ;
BLIZZARD, RM ;
HAMBRICK, GW .
ARCHIVES OF DERMATOLOGY, 1973, 107 (03) :407-412
[8]  
KROOK G, 1961, ACTA DERM-VENEREOL, V41, P178
[9]   Alopecia areata investigational assessment guidelines [J].
Olsen, E ;
Hordinsky, M ;
McDonald-Hull, S ;
Price, V ;
Roberts, J ;
Shapiro, J ;
Stenn, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (02) :242-246
[10]  
PRICE V H, 1987, Dermatologica (Basel), V175, P36